



ASX ANNOUNCEMENT

1 SEPTEMBER 2017

CANN GROUP JOINS MEDICINAL CANNABIS INFORMATION PORTAL

1 September 2017 – Melbourne-based Cann Group Limited (through its wholly-owned subsidiary Cannproducts Pty Ltd) is pleased to announce its inclusion as a partner in a Medicinal Cannabis Medicines Portal (MCMP), which will facilitate streamlined medicinal cannabis prescribing and dispensing in Australia.

The MCMP is a collaboration between prescribers, pharmacists and sponsor manufacturers to help patients access appropriate medicinal cannabis treatment in line with national and state/territory-based laws and requirements. It also provides logistics support for pharmacy wholesaler ordering and pharmacy dispensing.

Consultancy Sinapse and its specialised pharmaceutical system PharmaPrograms have developed the IT-based portal to bring transparency to the process, products and price certainty, for prescribing and dispensing medicinal cannabis in Australia.

From 12 September 2017, prescribers and pharmacists will be able to register for the MCMP system. In October 2017, health professionals, will facilitate streamlined patient access to the medicinal cannabis of participant manufacturers via the TGA's Special Access Scheme.

The portal will link health professionals, pharmacies and patients, and enable Cann Group to engage with patients and patient support groups via doctors and pharmacists.

PharmaPrograms provides bespoke Health Care Professional - Patient Programs facilitated across Prescribers and Community Pharmacy. Since 2013 some 5000 prescribers and 4300 pharmacies have participated in PharmaPrograms initiatives. Cann Group CEO Peter Crock said "as a leader in the medicinal cannabis sector, it was important for the Company to be involved in a portal that would provide vital information, via health professionals, to patients as the end-users of its products".

"The launch of the MCMP is a crucial step in making medicinal cannabis available to the people who need it via a diverse health professionals network, and Cann Group is proud to be part of it as the fledgling Australian medicinal cannabis industry grows."

Clinical Pharmacist and PharmaPrograms systems architect Kos Sclavos AM said it was looking forward to partnering with the likes of Cann Group to provide streamlined processes and information for health professionals and access to medicinal cannabis for patients and carers.

"The MCMP is a robust and proven IT platform that will give health professionals and partner portal companies the information they need to operate efficiently and effectively to support patients."

The portal is available at www.mcmp.com.au



For further information please contact:

Peter Crock
Cann Group Limited
+61 (0) 3 9095 7088
contact@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – Canada's second largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 19.9% shareholding.